|
|
||
|
|
|
|
The 21st Century is also identified as the “Century of Knowledge”, where knowledge is the driving force of the Economy. A nation's competitiveness comes from the tangible and intangible assets created through innovation and R&D. Biotechnology has always been one of the core categories in global development. |
|
|
|
||
|
|
|
|
|
10/2015 |
BioLite Inc. sponsored the International Symposium on Hematology and Oncology (ISHO). |
|
|
|
||
|
09/2015 |
BioLite Inc. won the Merit Award in the Bio-industry category of“2015 Bio-industry and Modern Agriculture Competition,”which was co-organized by Industrial Technology Research Institute, Taiwan Bio-industry Organization, Taipei Bio-industry Organization, and Epoch Foundation. |
|
|
|
||
|
09/2015 |
The Academy-Industry Co-operation Project granted by the Hsinchu Science Park for BLI-1008 has been accomplished. This project include pharmacology and pharmacokinetics studies in animals, and protocol design of phase II clinical trial. Half of the expenses were covered by government grants. |
|
|
|
||
|
06/2015 |
BioLite, Inc. was one of the leading companies which won the 2015 Annual Innovation Award from Taiwan Development & Research Academia of Economic & Technology. |
|
|
|
||
|
05/2015 |
The BioLite Inc. received 10 import licenses for dietary supplements. |
|
|
04/2015 |
The Phase II clinical trial of the new antidepressant drug- BLI-1005 received subvention under the fast track clinical trial evaluation program from Ministry of Economic Affairs. |
|
|
|
|
|
| 04/2015 |
Completed capital increase to NT$304.15 million. |
|
|
|
|
|
| 02/2015 |
Phase II clinical trial of BLI-1005 received permissions from IRBs of three contract clinical sites：Linkou Chang Gung Memorial Hospital, Taipei Veterans General Hospital, and Taipei City Hospital- Songde Branch. The first patient was recruited in May, 2015. |
|
| 11/2014 | Subvention grant received for the new cancer combination therapy BLI-1401 from Small and Medium Business Innovation Research (SBIR) plan, Ministry of Economic Affairs. | |
| 07/2014 | A phase 2 clinical trial for the new anti-depressant BLI-1005 approved by Food and Drug Administration, Taiwan (TFDA). | |
| 05/2014 | Subvention grant received for the new anti-ADHD medication BLI-1008 from R&D project, Hsinchu Science Park Bureau, Ministry of Science and Technology. | |
|
|
|
|
|
03/2014 |
Phase 2 clinical trial for the new anti-depressant BLI-1005 approved by US FDA. | |
|
|
|
|
|
02/2014 |
Stationed in Hsinchu Biomedical Science Park ,established the Biomedical Science Park Branch Office. Biomedical Research &Innovation Center. |
|
|
|
|
|
|
01/2014 |
Established Health Management Business Department and built the first Healthcare Management Center. |
|
|
|
|
|
|
10/2013 |
Completed phase I clinical trial and received positive results from the new anti-depressant BLI-1005. |
|
|
|
|
|
|
09/2013 |
Patents for the new anti-Inflammatory Bowel Disease drug BLI-1006 approved in China, USA, and EU. |
|
|
|
|
|
|
07/2013 |
Completed capital increase to NT$251.76 million, received positive recognition and support from the government, and obtained investment from National Development Fund, Executive Yuan, Taiwan. |
|
|
|
|
|
|
05/2013 |
Collaborated and signed licensing agreement with Yukiguni Maitake Co. Ltd., Japan for the new anti-Myelodysplastic Syndromes and anti-cancer drug, BLI-1301. |
|
|
|
|
|
|
05/2013 |
Subvention grant received for the new anti-depressant BLI-1005 from “Enhancement R&D Research Project”, Hsinchu Science Park Bureau, Ministry of Science and Technology. |
|
|
|
|
|
|
11/2012 |
Received subvention grant for the new anti-depressant BLI-1005 from Industrial Technology Development Program, Ministry of Economic Affairs. |
|
|
|
|
|
|
10/2012 |
A phase 1 clinical trial for the new anti-depressant BLI-1005 conducted in Taipei Veteran General Hospital. |
|
|
|
|
|
|
09/2012 |
Anti-Depressant Drug BLI-1005 met the criteria of 2012 “Cross-Strait Cooperative Pharmaceutical R&D Pilot Project Plan.” |
|
|
|
|
|
|
08/2012 |
Received IND approval for the new anti-depressant BLI-1005 by the Food and Drug Administration, Taiwan (TFDA). |
|
|
|
|
|
|
06/2012 |
BioLite and our 4 new product lines passed the evaluation and meet the criteria of “Act for the Development of Biotech and New Pharmaceuticals Industry.” |
|
|
|
|
|
|
02/2012 |
Received IND approval for the new anti-depressant BLI-1005 by US FDA. |
|
|
|
|
|
|
09/2011 |
Established Taipei Office in Neihui , Taipei City. |
|
|
|
|
|
|
02/2011 |
A “Licensing and Technical Transfer Agreement” signed with Industrial Technology Research Institute with the following technologies: (1) Technology platform for “Botanical Drug Development” |
|
|
|
|
|
|
02/2011 |
Increased Capital to NT$170 million by providing employee stock purchasing options with total value of NT$2 million. | |
| 01/2011 | Signed Exclusive Licensing Agreement on new anti-depressant PDC-1412 with Medical and Pharmaceutical Industry technology and Development Center. | |
| 03/2010 | Increased capital from NT$100 million to NT$168 million. | |
| 08/2009 | Increased capital from NT$50 million to NT $100 million. | |
| 08/2009 | Stationed in Hsinchu Science Park Bureau, Ministry of Science and Technology. | |
| 06/2009 | Obtained approval to establish company presence in Hsinchu Science Park Bureau, Ministry of Science and Technology. | |
| 12/2006 | Qualified as emerging industry under "Statute for Upgrading Industry" by Ministry of Economic Affairs. | |
| 07/2006 | Stationed in Innovative Incubation Center of Industrial Technology Research Institute. | |
| 06/2006 | Increased capital from NT$1 million to NT$ 50 million. | |
| 02/2006 | Approved to establish BioLite, Inc. with NT$ 1 Million Capital and based in Hsinchu City. | |
Major Events